Novel and Personalized Therapies for Multiple Myeloma and Plasma Cell Disorders (Volume II)

Dear Colleagues,

This collection is the second edition of "Novel and Personalized Therapies for Multiple Myeloma and Plasma Cell Disorders", which can be found at https://www.mdpi.com/journal/cancers/special_issues/mmpcd.

Multiple myeloma and other plasma cell dyscrasias are a heterogeneous group of disorders, producing monoclonal proteins that originate from the proliferation of monoclonal plasma cells and cause severe end organ damage, with fatal consequences. In the past two decades, major advances in therapy have occurred, resulting in better survival and quality of life, but more precise definitions of these disorders have also been developed. The introduction of novel agents and treatment modalities has advanced the field immensely. The availability of more options has made it both necessary and possible to individualize treatment. In this Special Issue, we would like to provide an update on the advances in novel and personalized therapies for multiple myeloma.

We are pleased to invite you to contribute to this Special Issue, which is intended to report an overview of the most recent diagnostic methods and monitoring techniques and to provide an in-depth description of specific patient care and outcomes with the latest individualized treatment approaches.

In this Special Issue, we welcome both original research articles and reviews on the broad spectrum of clinical characteristics, laboratory and clinical diagnosis, prognosis, pathophysiology, and treatment with respect to novel and personalized therapies for multiple myeloma and other plasma cell dyscrasias. We look forward to receiving your contributions.

Dr. Moshe Gatt
Dr. Efstathios Kastritis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• multiple myeloma
• plasma cell disorders
• novel therapies
• personalized therapies
• diagnosis and treatment